Folate-conjugated nanovehicles: Strategies for cancer therapy

Farran, Batoul; Montenegro, Raquel Carvalho; Kasa, Prameswari; Pavitra, E.; Huh, Yun Suk; Han, Young‐Kyu; Kamal, Mohammad Amjad; Nagaraju, Ganji Purnachandra; Raju, G. Seeta Rama

doi:10.1016/j.msec.2019.110341

Cited by 68 publications

(37 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[128][129][130] In addition, folate receptor is upregulated in many types of cancer cells. [130][131][132] Therefore, folic acid and folate derivatives have been widely used as promising ligands to selectively deliver imaging and therapeutic agents to cancer cells, TAMs, and activated macrophages in inflammatory diseases. [130][131][132][133] However, less studies have focused on the potential of macrophage targeting with folate functionalized nanocarriers in the field of intracellular infections.…”

Section: Folate Receptor Targetingmentioning

confidence: 99%

“…[130][131][132] Therefore, folic acid and folate derivatives have been widely used as promising ligands to selectively deliver imaging and therapeutic agents to cancer cells, TAMs, and activated macrophages in inflammatory diseases. [130][131][132][133] However, less studies have focused on the potential of macrophage targeting with folate functionalized nanocarriers in the field of intracellular infections. Such examples are the folic acid-decorated antiretroviral drug nanoformulations that displayed enhanced uptake by monocyte-derived macrophages and enhanced antiretroviral activities compared with nontargeted particles.…”

Section: Folate Receptor Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial‐loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment.

show abstract

Section: Folate Receptor Targetingmentioning

confidence: 99%

Section: Folate Receptor Targetingmentioning

confidence: 99%

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…For example, FA receptors and transporters are overexpressed in many types of cancers, including CRC. Therefore FA-coated liposomes are expected to exhibit increased uptake by cancer cells with overexpressed folate receptors [ 141 , 142 ]. E. Moghimipour et al showed that, in CT26 cells, FA-decorated liposomal 5-fluorouracil exhibited enhanced cellular uptake of the encapsulated 5-fluorouracil compared to free 5-fluorouracil, with a three-fold decrease in the IC 50 (12.02 versus 39.81 µM, respectively) and 25-fold higher ROS production (62,271.28 versus 2369.55 a.u., respectively, as shown by fluorescence intensity) [ 69 ].…”

Section: Deliverable Targets For Crc Treatmentmentioning

confidence: 99%

Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy

Yang

Merlin

2020

Nanomaterials

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a prevalent disease worldwide, and patients at late stages of CRC often suffer from a high mortality rate after surgery. Adjuvant chemotherapeutics (ACs) have been extensively developed to improve the survival rate of such patients, but conventionally formulated ACs inevitably distribute toxic chemotherapeutic drugs to healthy organs and thus often trigger severe side effects. CRC cells may also develop drug resistance following repeat dosing of conventional ACs, limiting their effectiveness. Given these limitations, researchers have sought to use targeted drug delivery systems (DDSs), specifically the nanotechnology-based DDSs, to deliver the ACs. As lipid-based nanoplatforms have shown the potential to improve the efficacy and safety of various cytotoxic drugs (such as paclitaxel and vincristine) in the clinical treatment of gastric cancer and leukemia, the preclinical progress of lipid-based nanoplatforms has attracted increasing interest. The lipid-based nanoplatforms might be the most promising DDSs to succeed in entering a clinical trial for CRC treatment. This review will briefly examine the history of preclinical research on lipid-based nanoplatforms, summarize the current progress, and discuss the challenges and prospects of using such approaches in the treatment of CRC.

show abstract

“…Dendrimers have a well-defined macromolecular structure, spherical geometry and abundant functional groups on the surface that can be modified or physically changed for nontoxicity, enhanced efficiency and specific cargo abilities [12]. Research studies consider dendrimers as delivery systems for drugs, genes and contrast agents [13]. There are few different types of compounds used for preparation of dendrimers, e.g., poly(propylene imine) (PPI), poly(Llysine), poly(amidoamine) (PAMAM), PAMAM-organosilicon (PAMAMOS).…”

Section: Introductionmentioning

confidence: 99%

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major causes of death worldwide and its treatment remains very challenging. The effectiveness of cancer therapy significantly depends upon tumour-specific delivery of the drug. Nanoparticle drug delivery systems have been developed to avoid the side effects of the conventional chemotherapy. However, according to the most recent recommendations, future nanomedicine should be focused mainly on active targeting of nanocarriers based on ligand-receptor recognition, which may show better efficacy than passive targeting in human cancer therapy. Nevertheless, the efficacy of single-ligand nanomedicines is still limited due to the complexity of the tumour microenvironment. Thus, the NPs are improved toward an additional functionality, e.g., pH-sensitivity (advanced single-targeted NPs). Moreover, dual-targeted nanoparticles which contain two different types of targeting agents on the same drug delivery system are developed. The advanced single-targeted NPs and dual-targeted nanocarriers present superior properties related to cell selectivity, cellular uptake and cytotoxicity toward cancer cells than conventional drug, non-targeted systems and single-targeted systems without additional functionality. Folic acid and biotin are used as targeting ligands for cancer chemotherapy, since they are available, inexpensive, nontoxic, nonimmunogenic and easy to modify. These ligands are used in both, single- and dual-targeted systems although the latter are still a novel approach. This review presents the recent achievements in the development of single- or dual-targeted nanoparticles for anticancer drug delivery.

show abstract

Folate-conjugated nanovehicles: Strategies for cancer therapy

Cited by 68 publications

References 149 publications

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy

Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery

Contact Info

Product

Resources

About